 Altimmune Inc NASDAQ: ALT has announced results from a 12-week, Phase 1 trial of pemvidutide ALT-801, an investigational glucagon-like peptide-1 GLP-1glucagon dual receptor agonist. At 12 weeks, those who received pemvidutide achieved mean weight losses of 4.9, 10.3, and 9.0 at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, compared to 1.6 weight loss in the placebo group. 